|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial : Rationale and design
| Title: | Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial : Rationale and design |
| Authors: | Osanai, Toshiya Browse this author →KAKEN DB | | Houkin, Kiyohiro Browse this author →KAKEN DB | | Uchiyama, Shinichiro Browse this author | | Minematsu, Kazuo Browse this author | | Taguchi, Akihiko Browse this author | | Terasaka, Shunsuke Browse this author →KAKEN DB |
| Keywords: | Cell therapy | | ischemic stroke | | clinical trial |
| Issue Date: | 1-Jun-2018 |
| Publisher: | SAGE Publications |
| Journal Title: | International journal of stroke |
| Volume: | 13 |
| Issue: | 4 |
| Start Page: | 444 |
| End Page: | 448 |
| Publisher DOI: | 10.1177/1747493017743057 |
| PMID: | 29134924 |
| Abstract: | Rationale: MultiStem® (HLM051) is one of the promising allogenic cell products for acute ischemic stroke with strong evidence. A previous phase 2 randomized, double-blind, placebo-controlled, multicenter dose-escalation trial showed the safety of MultiStem® for acute ischemic stroke, with a time window beyond that of rt-PA and endovascular thrombectomy. We aim to obtain stronger evidence and to show the efficacy of the MultiStem® for treatment of ischemic stroke. Sample size: Estimated sample size is 220 (110 patients per group), which has 90% power at 5% significance level. Methods and design: TREASURE is a randomized, double-blind, placebo-controlled, multicenter phase 2/3 trial. The trial will be done at 31 medical centers in Japan. Patients with acute ischemic stroke including motor or speech deficit defined by a National Institution of Health Stroke Scale (NIHSS) score of 8-20 at baseline will be randomized 1:1 to receive a single intravenous infusion of MultiStem® or placebo within 18-36 h of stroke onset. Study outcomes: Primary outcome in this study is the proportion of patients with an excellent outcome at day 90 defined by the functional assessment. Trial registration: ClinicalTrials.gov (NCT02961504). Conclusion: The TREASURE trial will provide a novel treatment option and expand the therapeutic window for patients with stroke if the results are positive. |
| Rights: | Toshiya Osanai, Kiyohiro Houkin, Shinichiro Uchiyama, Kazuo Minematsu, Akihiko Taguchi, and Shunsuke Terasaka, Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial : Rationale and design., International Journal of Stroke (Vol 13, Issue 4) pp.444-448. Copyright © 2018, SAGE Publications. Reprinted by permission of SAGE Publications. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/70999 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 長内 俊也
|
